Cover Image
市場調查報告書

氣喘:全球8個國家的市場預測

Asthma Forecast in 8 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 370679
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
氣喘:全球8個國家的市場預測 Asthma Forecast in 8 Major Markets 2016-2026
出版日期: 2016年09月16日 內容資訊: 英文 60 Pages
簡介

本報告提供全球主要8個國家 (美國、法國、德國、義大利、西班牙、英國、巴西、日本) 的氣喘治療的市場相關分析,各國的氣喘患病人數的變化和未來預測 (今後10年份),男女、各年齡層 (5歲分級) 及各重症度的詳細趨勢、主要的併發症 (抽煙、肥胖、COPD (慢性阻塞性肺病)、GERD (胃食道逆流症)、睡眠障礙等)的罹患情形,主要的風險要素,預後的差異 (各地區、各民族等),現在、未來的主要的治療方法,診斷、治療的實施情形等的調查評估。

目錄

  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷
  • 各地區、各民族的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要並存症/特徵
  • 患者數的定量化方法
  • 惡病質的患病人數的最大估計值 (top line)
  • 氣喘的患者數:各特徵
    • 各重症度 (GINA指南)
    • 各表現型 (Haldar標準)
    • SARP式的各表現型
  • 難治性氣喘 (非常難管理)
    • 特異反應性型/非特異反應性型
    • 嗜酸性粒細胞 (EOS)的各水準
    • 各BMI (肥胖度指數)
    • 各抽煙狀況
  • 使用支氣管擴張劑的氣喘的治療
  • 氣喘的預防性治療
    • 氣喘患者的併發症
  • 氣喘患者的醫療機關的使用概況
  • 本文中的簡稱
  • 關於相關分析、資料庫
  • 註腳
  • 附錄

圖表一覽

目錄
Product Code: ATMA010816

image1

Asthma is a chronic disease involving airway inflammation, reversible airflow obstruction, and bronchial hyper-responsiveness. The condition is usually triggered by environmental factors of which the symptoms include: difficulty breathing, coughing, wheezing and in some cases a life-threatening asthma attack. Although the condition is not currently curable, the symptoms can be controlled to a more manageable state through stepping up and stepping down treatments according to disease progression.

This report provides the current prevalent population for Asthma across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Asthma have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

The main co-morbidities associated with asthma include:

  • Obesity
  • Smoking
  • COPD
  • GERD
  • Sleep disorders

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in the global Asthma market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Asthma and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Asthma's prevalent population.
  • Identify sub-populations within Asthma which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Asthma patients.

Coverage

BR, FR, DE, IT, JP, ES, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Cachexia

Features of Asthma Patients

  • Asthma by Severity (GINA)
  • Asthma by Phenotype (Haldar)
  • Asthma by SARP Phenotype

Refractory (Severe Uncontrolled) Asthma

  • Asthma by Atopic Sub-type
  • Asthma by EOS + Sub-type
  • Asthma by BMI Status
  • Asthma by Smoking Status

Treatment of Asthma with Bronchodilators

Preventative treatment of Asthma

  • Comorbidities in Asthma Patients

Healthcare Utilisation by patients with Asthma

Abbreviations used in the report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Figures

  • Clinical phenotypes of asthma using cluster analysis
  • Stepwise approach to treatment

List of Tables

  • GINA Classification parameters
  • Prevalence of Asthma, total (000s)
  • Prevalence of Asthma, , males (000s)
  • Prevalence of Asthma , females (000s)
  • Asthma patients by severity, total (000s)
  • Asthma patients by Phenotype (Haldar), total (000s)
  • Asthma patients by SARP Phenotype, total (000s)
  • Prevalence of Refractory (Severe Uncontrolled) Asthma, total (000s)
  • Asthma patients by Atopic sub-type, total (000s)
  • Asthma patients by EOS + sub-type, total (000s)
  • Asthma patients by BMI status, total (000s)
  • Asthma patients by smoking status, total (000s)
  • Treatment of asthma with quick-acting bronchodilators, total (000s)
  • Treatment of asthma with quick-acting bronchodilators by asthma severity (000s)
  • Patients with Asthma receiving preventative treatment, total (000s)
  • Patients receiving preventative treatment by asthma severity (000s)
  • Prevalence of GERD in Patients with Moderate & Severe Asthma, total (000s)
  • Prevalence of Diabetes in Patients with Moderate & Severe Asthma, total (000s)
  • Prevalence of COPD in asthma patients, total (000s)
  • Prevalence of Atopic Dermatitis in asthma patients, total (000s)
  • Hospitalised overnight due to asthma in past 12 months, total (000s)
  • Visited ER due to asthma in past 12 months, total (000s)
  • Unscheduled medical visit due to asthma in past 12 months, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Asthma by 5-yr age cohort, males (000s)
  • USA Prevalence of Asthma by 5-yr age cohort, females (000s)
  • France Prevalence of Asthma by 5-yr age cohort, males (000s)
  • France Prevalence of Asthma by 5-yr age cohort, females (000s)
  • Germany Prevalence of Asthma by 5-yr age cohort, males (000s)
  • Germany Prevalence of Asthma by 5-yr age cohort, females (000s)
  • Italy Prevalence of Asthma by 5-yr age cohort, males (000s)
  • Italy Prevalence of Asthma by 5-yr age cohort, females (000s)
  • Spain Prevalence of Asthma by 5-yr age cohort, males (000s)
  • Spain Prevalence of Asthma by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Asthma by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Asthma by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Asthma by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Asthma by 5-yr age cohort, females (000s)
  • Japan Prevalence of Asthma by 5-yr age cohort, males (000s)
  • Japan Prevalence of Asthma by 5-yr age cohort, females (000s)
Back to Top